日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Genomic alterations are associated with response to aromatase inhibitor therapy for ER-positive postmenopausal ductal carcinoma in situ: (CALGB 40903, Alliance)

基因组改变与雌激素受体阳性绝经后导管原位癌对芳香化酶抑制剂治疗的反应相关:(CALGB 40903,Alliance)

Marks, Jeffrey R; Zhang, Dadong; Hardman, Timothy; Chen, Yunn-Yi; Hall, Allison; Simpson, Lunden; Hieken, Tina; Bedrosian, Isabelle; Price, Elissa; Sheng, Jeff; Dai, Yanwan; Lee, Marissa; Sibley, Alexander B; Owzar, Kouros; Hwang, E Shelley

Malignant phyllodes tumours of the breast: the case for revising WHO's 'full house' diagnostic criteria

乳腺恶性叶状肿瘤:修订世卫组织“满堂红”诊断标准的必要性

Tan, Puay Hoon; Ellis, Ian O; Allison, Kimberly H; Badve, Sunil S; Brogi, Edi; Callagy, Grace; Charafe-Jauffret, Emmanuelle; Chen, Chih-Jung; Chen, Yunn-Yi; Collins, Laura C; Cserni, Gábor; Djerroudi, Lounes; Foschini, Maria Pia; Fox, Stephen B; Gobbi, Helenice; Gudi, Mihir; Harada, Oi; Jaffer, Shabnam; Kulka, Janina; Kuroda, Hajime; Lakhani, Sunil R; Li, Xiaoxian; Moriya, Takuya; O'Toole, Sandra; Pinder, Sarah E; Provenzano, Elena; Quinn, Cecily; Raymond, Wendy; Sahin, Aysegul A; Schmitt, Fernando; Shaaban, Abeer M; Shet, Tanuja; Siziopikou, Kalliopi P; Tang, Ping; Tse, Gary M; Varga, Zsuzsanna; Vincent-Salomon, Anne; Wen, Hannah; Yamaguchi, Rin; Yang, Wentao; Schnitt, Stuart J; Rakha, Emad A

NCOR2 represses MHC class I molecule expression to drive metastatic progression of breast cancer.

NCOR2抑制MHC I类分子表达,从而促进乳腺癌的转移进展

Ticha Pavla, Northey Jason J, Kersten Kelly, Velozo Hugo González, Ironside Alastair J, Zidek Martin, Drain Allison, Lakins Jonathan N, Chen Yunn-Yi, Tsai Kelvin K, Weaver Valerie M

Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery

新辅助Trebananib联合紫杉醇化疗治疗II/III期乳腺癌:适应性随机I-SPY2试验的疗效和生物标志物发现

Albain, Kathy S; Yau, Christina; Petricoin, Emanuel F; Wolf, Denise M; Lang, Julie E; Chien, A Jo; Haddad, Tufia; Forero-Torres, Andres; Wallace, Anne M; Kaplan, Henry; Pusztai, Lajos; Euhus, David; Nanda, Rita; Elias, Anthony D; Clark, Amy S; Godellas, Constantine; Boughey, Judy C; Isaacs, Claudine; Tripathy, Debu; Lu, Janice; Yung, Rachel L; Gallagher, Rosa I; Wulfkuhle, Julia D; Brown-Swigart, Lamorna; Krings, Gregor; Chen, Yunn Yi; Potter, David A; Stringer-Reasor, Erica; Blair, Sarah; Asare, Smita M; Wilson, Amy; Hirst, Gillian L; Singhrao, Ruby; Buxton, Meredith; Clennell, Julia L; Sanil, Ashish; Berry, Scott; Asare, Adam L; Matthews, Jeffrey B; DeMichele, Angela M; Hylton, Nola M; Melisko, Michelle; Perlmutter, Jane; Rugo, Hope S; Symmans, W Fraser; Van't Veer, Laura J; Yee, Douglas; Berry, Donald A; Esserman, Laura J

Change in Biomarker Profile After Neoadjuvant Chemotherapy is Prognostic and Common Among Patients with HER2+ Breast Cancer

新辅助化疗后生物标志物谱的变化具有预后价值,且在HER2阳性乳腺癌患者中较为常见

Tchou, Julia; Gottipati, Soumy; Goldbach, Macy; Baxter, Molly; Venters, Sara; Balassanian, Ron; Vohra, Poonam; Gonzalves, Diego; Ahmad, Zahra; Nayak, Anupma; Boughey, Judy C; Mukhtar, Rita A; Chen, Yunn-Yi

Clinicopathologic and genetic analysis of invasive breast carcinomas in women with germline CHEK2 variants

对携带生殖系CHEK2变异的女性的浸润性乳腺癌进行临床病理学和遗传学分析

Schwartz, Christopher J; Khorsandi, Nikka; Blanco, Amie; Mukhtar, Rita A; Chen, Yunn-Yi; Krings, Gregor

Loss of PPARγ activity characterizes early protumorigenic stromal reprogramming and dictates the therapeutic window of opportunity

PPARγ活性的丧失是早期促肿瘤基质重编程的特征,并决定了治疗的窗口期。

Caruso, Joseph A; Wang, Xianhong; Murrow, Lyndsay M; Rodriguez, Carlos Ivan; Chen-Tanyolac, Chira; Vu, Lisa; Chen, Yunn-Yi; Gascard, Philippe; Gartner, Zev J; Kerlikowske, Karla; Tlsty, Thea D

Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial

新辅助I-SPY2试验中残余导管原位癌与乳腺癌复发的相关性

Osdoit, Marie; Yau, Christina; Symmans, W Fraser; Boughey, Judy C; Ewing, Cheryl A; Balassanian, Ron; Chen, Yunn-Yi; Krings, Gregor; Wallace, Anne M; Zare, Somaye; Fadare, Oluwole; Lancaster, Rachael; Wei, Shi; Godellas, Constantine V; Tang, Ping; Tuttle, Todd M; Klein, Molly; Sahoo, Sunati; Hieken, Tina J; Carter, Jodi M; Chen, Beiyun; Ahrendt, Gretchen; Tchou, Julia; Feldman, Michael; Tousimis, Eleni; Zeck, Jay; Jaskowiak, Nora; Sattar, Husain; Naik, Arpana M; Lee, Marie Catherine; Rosa, Marilin; Khazai, Laila; Rendi, Mara H; Lang, Julie E; Lu, Janice; Tawfik, Ossama; Asare, Smita M; Esserman, Laura J; Mukhtar, Rita A

Correction to: Genetic and immunohistochemical profiling of small cell and large cell neuroendocrine carcinomas of the breast

更正:乳腺小细胞和大细胞神经内分泌癌的遗传和免疫组织化学分析

Bean, Gregory R; Najjar, Saleh; Shin, Sandra J; Hosfield, Elizabeth M; Caswell-Jin, Jennifer L; Urisman, Anatoly; Jones, Kirk D; Chen, Yunn-Yi; Krings, Gregor

Genetic and immunohistochemical profiling of small cell and large cell neuroendocrine carcinomas of the breast

乳腺小细胞和大细胞神经内分泌癌的遗传和免疫组织化学分析

Bean, Gregory R; Najjar, Saleh; Shin, Sandra J; Hosfield, Elizabeth M; Caswell-Jin, Jennifer L; Urisman, Anatoly; Jones, Kirk D; Chen, Yunn-Yi; Krings, Gregor